{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:09:05Z","timestamp":1784830145736,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Indacaterol\/glycopyrronium (IND\/GLY) 110\/50\u2009\u03bcg once daily (q.d.) has demonstrated greater improvements in lung function, patient\u2010reported outcomes and lower exacerbation rates versus mono long\u2010acting muscarinic antagonists (LAMA) in chronic obstructive pulmonary disease (COPD) patients. However, data are limited on initial treatment with IND\/GLY 110\/50\u2009\u03bcg q.d. versus mono LAMA in COPD patients, not previously on maintenance treatment with long\u2010acting bronchodilators (LABD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A pooled analysis of ARISE, SHINE and SPARK trials was conducted to evaluate the efficacy of IND\/GLY 110\/50\u2009\u03bcg q.d. versus open\u2010label (OL) tiotropium (TIO) 18\u2009\u03bcg q.d. and GLY 50\u2009\u03bcg q.d. in COPD patients, not on maintenance treatment with LABD at study entry (LABD\u2010na\u00efve). Efficacy was assessed after 24\/26\u2009weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 998 LABD\u2010na\u00efve patients were included (IND\/GLY: 353; OL TIO: 328; GLY: 317). Patients treated with IND\/GLY 110\/50\u2009\u03bcg q.d. experienced greater improvements in trough forced expiratory volume in 1 s (FEV<jats:sub>1<\/jats:sub>) versus OL TIO 18\u2009\u03bcg q.d. (least squares mean treatment difference (\u0394): 0.086\u2009L) and GLY 50\u2009\u03bcg q.d. (\u0394: 0.080\u2009L) after 24\/26\u2009weeks. Improvements in electronic diary (eDiary) symptom scores, transition dyspnoea index (TDI) focal score, St George's Respiratory Questionnaire (SGRQ) total score and rescue medication use were also greater with IND\/GLY versus OL TIO and GLY. Greater proportion of patients achieved minimal clinically important difference in trough FEV<jats:sub>1<\/jats:sub>, TDI and SGRQ with IND\/GLY versus OL TIO and GLY.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LABD\u2010na\u00efve patients treated with IND\/GLY 110\/50\u2009\u03bcg q.d. achieved improvements in lung function, daily symptoms, dyspnoea, health\u2010related quality of life and rescue medication use versus those who received single LAMA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.13651","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T13:47:03Z","timestamp":1563976023000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long\u2010acting bronchodilator\u2010na\u00efve COPD patients: A pooled analysis"],"prefix":"10.1111","volume":"25","author":[{"given":"Shigeo","family":"Muro","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-3211","authenticated-orcid":false,"given":"Hajime","family":"Yoshisue","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K. Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3942","authenticated-orcid":false,"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department University of Ioannina Medical School  Ioannina Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Olsson","sequence":"additional","affiliation":[{"name":"Novartis Sverige AB  Kista Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritam","family":"Gupta","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S138554"},{"key":"e_1_2_10_3_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease 2019. [Accessed 16 Nov 2018.] Available from URL:http:\/\/goldcopd.org\/gold-reports\/"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00200212"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70052-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","unstructured":"WedzichaJA BanerjiD ChapmanKR VestboJ RocheN AyersRT ThachC FogelR PatalanoF VogelmeierCF;FLAME Investigators. Indacaterol\u2010glycopyrronium versus salmeterol\u2010fluticasone for COPD.N. Engl. J. Med.2016;374:2222\u201334.","DOI":"10.1056\/NEJMoa1516385"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0430-6"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0218-0"},{"key":"e_1_2_10_9_1","unstructured":"Ultibro Breezhaler: Summary of Product Characteristics. [Accessed 16 Nov 2018.] Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002679\/WC500151255.pdf"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.10.015"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S160577"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.06.004"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2613"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.00852"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008378"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","unstructured":"WiseRA AnzuetoA CottonD DahlR DevinsT DisseB DusserD JosephE KattenbeckS Koenen\u2010BergmannMet al.;TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD.N. Engl. J. Med.2013;369:1491\u2013501.","DOI":"10.1056\/NEJMoa1303342"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-156"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040712"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S32451"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2016.06.006"},{"key":"e_1_2_10_22_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease 2008."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200053377"},{"key":"e_1_2_10_24_1","first-page":"79","article-title":"Symptoms and impact of COPD assessed by an electronic diary in patients with moderate\u2010to\u2010severe COPD: psychometric results from the SHINE study","volume":"10","author":"Kulich K","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2018.0040"},{"key":"e_1_2_10_28_1","volume-title":"Fundamentals of Clinical Trials","author":"Friedman LM","year":"2005"},{"key":"e_1_2_10_29_1","first-page":"381","article-title":"Early response to inhaled bronchodilators and corticosteroids as a predictor of 12\u2010month treatment responder status and COPD exacerbations","volume":"11","author":"Calverley PM","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0387-7"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1843.2003.00501.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.1.106"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S27480"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/npjpcrm.2014.3"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1074678"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S62750"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2010.00059"},{"key":"e_1_2_10_38_1","first-page":"CD010115","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"3","author":"Kew KM","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00037-2017"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.06.019"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.07.002"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.07.011"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S130482"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02245-2016"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/resp.13651","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:04:16Z","timestamp":1694037856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/resp.13651"],"URL":"https:\/\/doi.org\/10.1111\/resp.13651","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"2018-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}